triple agonist retatrutide Obesity Targeting Glp-1 Stock Photo 2639191569 Today, we shared new data

As with other incretin-based therapies, the most commonly reported adverse effects in the retatrutide phase 2 trial were gastrointestinal in nature

Refills Health LLC is a technology platform not a medical services provider

Investigational regulatory status Retatrutide is not FDA-approved for any indication

Questions to Discuss With Your Healthcare Provider Before pursuing any weight loss medication, prepare to discuss: Your complete medical history including any conditions that might represent contraindications

Baseline bloodwork should be completed before the first injection

Bridge Nutritional Gaps with Rock the Shot Given the appetite-suppressing effects of GLP-1 medications, meeting your daily nutritional requirements can be challenging